1. Manley H, Sisk BA, Master Z, Scott CT. Prescribing unproven cancer drugs: physician perspectives on expanded access and right to try. J Law Biosci. 2022 Jul-Dec; 9 (2):lsac031 Epub 2022 Oct 25
    View PubMed
  2. Arthurs JR, Nordan LM, Hultgren BH, Heckman MG, Martinez D, Master Z, Shapiro SA. Patients seeking stem cell therapies-a prospective qualitative analysis from a Regenerative Medicine Consult Service. NPJ Regen Med. 2022 Mar 25; 7 (1):20
    View PubMed
  3. Matthews KRW, Kawam O, Sprung K, Perin EC, Master Z. Role of Physicians in Guiding Patients Away From Unproven Stem Cell Interventions. Tex Heart Inst J 2022 Mar 1; 49 (2)
    View PubMed
  4. Physicians’ role in addressing patient misinformation about unproven stem cell therapies Texas Heart Institute Journal (In Press).. 2022.
  5. Arthurs JR, Martin Lillie CM, Master Z, Shapiro SA. The Direct to Consumer Stem Cell Market and the Role of Primary Care Providers in Correcting Misinformation. J Prim Care Community Health. 2022 Jan-Dec; 13:21501319221121460
    View PubMed
  6. Smith C, Crowley A, Munsie M, Behfar A, DeMartino ES, Staff NP, Shapiro SA, Master Z. Academic Physician Specialists' Approaches to Counseling Patients Interested in Unproven Stem Cell and Regenerative Therapies-A Qualitative Analysis. Mayo Clin Proc. 2021 Dec; 96 (12):3086-3096 Epub 2021 Aug 26
    View PubMed
  7. Finnoff JT, Awan TM, Borg-Stein J, Harmon KG, Herman DC, Malanga GA, Master Z, Mautner KR, Shapiro SA. American Medical Society for Sports Medicine Position Statement: Principles for the Responsible Use of Regenerative Medicine in Sports Medicine. Clin J Sport Med. 2021 Nov 1; 31 (6):530-541
    View PubMed
  8. Master Z, Matthews KRW, Abou-El-Enein M. Unproven stem cell interventions: A global public health problem requiring global deliberation. Stem Cell Reports. 2021 Jun 8; 16 (6):1435-1445
    View PubMed
  9. Smith C, Stout J, Adjei AA, Buckner J, Wentworth M, Tilburt J, Master Z. "I Think It's Been Met With a Shrug:" Oncologists' Views Toward and Experiences With Right-to-Try. J Natl Cancer Inst. 2021 Jun 1; 113 (6):735-741
    View PubMed
  10. Helgesson G, Master Z, Bulow W. How to Handle Co-authorship When Not Everyone's Research Contributions Make It into the Paper. Sci Eng Ethics. 2021 Apr 12; 27 (2):27
    View PubMed
  11. Smith C, Crowley A, Munsie M, DeMartino ES, Staff NP, Shapiro S, Master Z. Academic physician specialists' views toward the unproven stem cell intervention industry: areas of common ground and divergence. Cytotherapy. 2021 Apr; 23 (4):348-356 Epub 2021 Feb 06
    View PubMed
  12. Ohde JW, Master Z, Tilburt JC, Warner DO. Presumed Consent With Opt-Out: An Ethical Consent Approach to Automatically Refer Patients With Cancer to Tobacco Treatment Services. J Clin Oncol. 2021 Mar 10; 39 (8):876-880 Epub 2021 Jan 13
    View PubMed
  13. Stout J, Smith C, Buckner J, Adjei AA, Wentworth M, Tilburt JC, Master Z. Oncologists' reflections on patient rights and access to compassionate use drugs: A qualitative interview study from an academic cancer center. PLoS One. 2021; 16 (12):e0261478 Epub 2021 Dec 17
    View PubMed
  14. Master Z, Crowley AP, Smith C, Wigle D, Terzic A, Sharp RR. Stem cell preservation for regenerative therapies: ethical and governance considerations for the health care sector. NPJ Regen Med. 2020 Dec 1; 5 (1):23 Epub 2020 Dec 01
    View PubMed
  15. Smith E, Williams-Jones B, Master Z, Lariviere V, Sugimoto CR, Paul-Hus A, Shi M, Resnik DB. Misconduct and Misbehavior Related to Authorship Disagreements in Collaborative Science. Sci Eng Ethics. 2020 Aug; 26 (4):1967-1993 Epub 2019 June 03
    View PubMed
  16. Smith E, Williams-Jones B, Master Z, Lariviere V, Sugimoto CR, Paul-Hus A, Shi M, Diller E, Caudle K, Resnik DB. Researchers' Perceptions of Ethical Authorship Distribution in Collaborative Research Teams. Sci Eng Ethics. 2020 Aug; 26 (4):1995-2022 Epub 2019 June 04
    View PubMed
  17. Richardson E, Akkas F, Master Z. Evaluating the FDA regenerative medicine framework: opportunities for stakeholders. Regen Med 2020 Jul; 15 (7):1825-1832 Epub 2020 Aug 20
    View PubMed
  18. Resnik DB, Smith E, Master Z, Shi M. Survey of equal contributions in biomedical research publications. Account Res. 2020 Apr; 27 (3):115-137 Epub 2020 Feb 08
    View PubMed
  19. Smith C, Martin-Lillie C, Higano JD, Turner L, Phu S, Arthurs J, Nelson TJ, Shapiro S, Master Z. Challenging misinformation and engaging patients: characterizing a regenerative medicine consult service. Regen Med. 2020 Mar; 15 (3):1427-1440 Epub 2020 Apr 22
    View PubMed
  20. Meagher KM, Allyse MA, Master Z, Sharp RR. Reexamining the Ethics of Human Germline Editing in the Wake of Scandal. Mayo Clin Proc. 2020 Feb; 95 (2):330-338
    View PubMed
  21. Marcon A, Master Z, Ravitsky V, Caulfield T. CRISPR in the North American popular press. Genet Med. 2019 Oct; 21 (10):2184-2189 Epub 2019 Apr 12
    View PubMed
  22. Fu W, Smith C, Turner L, Fojtik J, Pacyna JE, Master Z. Characteristics and Scope of Training of Clinicians Participating in the US Direct-to-Consumer Marketplace for Unproven Stem Cell Interventions. JAMA. 2019 Jun 25; 321 (24):2463-2464
    View PubMed
  23. Hawke B, Przybylo AR, Paciulli D, Caulfield T, Zarzeczny A, Master Z. How to Peddle Hope: An Analysis of YouTube Patient Testimonials of Unproven Stem Cell Treatments. Stem Cell Reports. 2019 Jun 11; 12 (6):1186-1189
    View PubMed
  24. Master, Malik ,, Parker ,, DeCoster ,, Campo-Engelstein ,. In our words: a qualitative exploration of complex patient-provider interactions in an LGBTQ population. 2019 Canadian Journal of Bioethics. 2(2):83-93. 2019.
  25. Master Z, Caulfield, T, Marcon, A.R., Murdoch, B, Brown, J.M., Perrault, S.T., Jarry, J, Snyder, J, Anthony, S.J., Brooks, S., Rachul, C, Ogbogu, U., Greenberg, J., Zarzeczny, A, Hyde-Lay, R.. Health misinformation and the power of narrative messaging in the public sphere. Canadian Journal of Bioethics 2(2): 52-60. 2019.
  26. Shapiro SA, Smith CG, Arthurs JR, Master Z. Preparing regenerative therapies for clinical application: proposals for responsible translation. Regen Med. 2019 Feb; 14 (2):77-84 Epub 2019 Jan 17
    View PubMed
  27. Master Z, Tenenbaum E. The advantages of peer review over arbitration for resolving authorship disputes. Res Integr Peer Rev. 2019; 4:10 Epub 2019 May 30
    View PubMed
  28. Bubela T, Kleiderman E, Master Z, Ogbogu U, Ravitsky V, Zarzeczny A, Knoppers BM. Canada's Assisted Human Reproduction Act: Pragmatic Reforms in Support of Research. Front Med (Lausanne). 2019; 6:157 Epub 2019 July 10
    View PubMed
  29. Zarzeczny A, Atkins H, Illes J, Kimmelman J, Master Z, Robillard JM, Snyder J, Turner L, Zettler PJ, Caulfield T. The stem cell market and policy options: a call for clarity. J Law Biosci. 2018 Dec; 5 (3):743-758 Epub 2018 Nov 20
    View PubMed
  30. Greene M, Master Z. Ethical Issues of Using CRISPR Technologies for Research on Military Enhancement. J Bioeth Inq. 2018 Sep; 15 (3):327-335 Epub 2018 July 02
    View PubMed
  31. Master Z, Werner K, Smith E, Resnik DB, Williams-Jones B. Conflicts of interest policies for authors, peer reviewers, and editors of bioethics journals. AJOB Empir Bioeth. 2018 Jul-Sep; 9 (3):194-205 Epub 2018 Sept 24
    View PubMed
  32. Master Z, Bedford P. CRISPR Gene Editing Should Be Allowed in Canada, But Under What Circumstances? J Obstet Gynaecol Can. 2018 Feb; 40 (2):224-226 Epub 2017 Oct 12
    View PubMed
  33. Ogbogu U, Zarzeczny A, Baltz J, Bedford P, Du J, Hyun I, Jaafar Y, Jurisicova A, Kleiderman E, Koukio Y, Knoppers BM, Leader A, Master Z, Nguyen MT, Noohi F, Ravitsky V, Toews M. Research on Human Embryos and Reproductive Materials: Revisiting Canadian Law and Policy. Healthc Policy. 2018 Feb; 13 (3):10-19
    View PubMed
  34. Horner C, Tenenbaum E, Sipp D, Master Z. Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions. NPJ Regen Med. 2018; 3:5 Epub 2018 Feb 19
    View PubMed
  35. Master Z, Fu W, Paciulli D, Sipp D. Industry Responsibilities in Tackling Direct-to-Consumer Marketing of Unproven Stem Cell Treatments. Clin Pharmacol Ther. 2017 Aug; 102: (2)177-179.
    View PubMed
  36. Illes J, Sipp D, Kleiderman E, Benjaminy S, Isasi R, Master Z, Ogbogu U, Ravitsky V, Robilliard J, Zarzeczny A. A blueprint for the next generation of ELSI research, training, and outreach in regenerative medicine. Nature Regenerative Medicine..2017;
  37. Smith E, Master Z. Best practice to order authors in multi/interdisciplinary health sciences research publications. Accountability in Research: Policies and Quality Assurance..2017;24:(4)243-267.
  38. Murdoch B, Ravitsky V, Ogbogu U, Ali-Kahn S, Bertier G, Birko S, Bubela T, DeBeer J, Dupras C, Moreno P, Ellis M, Granados Moreno P, Joly Y, Kamenova K, Master Z, Marcon A, Paulden M, Rousseau F, Caulfield T. Non-invasive prenatal testing and the unveiling of an impaired translation process. Journal of Obstetrics and Gynaecology Canada.2017;39:(1)10-17.
  39. Master Z, McDonald M, Paciulli D, Longstaff H. A primer on ethics education for stem call and biomedical scientists. Current Stem Cell Reports..2016;2:(4)336-348.
  40. Master Z. A mentoring opportunity: a joint effort in writing letters of recommendation. Accountability in Research: Policies and Quality Assurance.2016;24:(1)52-59.
  41. Ferguson A, Master Z. Multisite research ethics review: problems and potential solutions BioethiqueOnline.2016;5:7.
  42. Caulfield T, Kamenova K, Ogbogu U, Zarzeczny A, Baltz J, Benjaminy S, Cassar P, Clark M, Isasi R, Knoppers B, Knowles L, Korbutt G, Lavery J, Lomax G, Master Z, McDonald M, Preto N, Toews M. Research ethics and stem cells: is it time to re-think current approaches to oversight? EMBO Reports. 2015; 23(5):569-574.
  43. Campo-Engelstein L, Santacrose L, Master Z, Parker W. Bad moms, blameless dads: are the portrayal of maternal and paternal age and preconception harm in US newspapers. AJOB Empirical Bioethics.2015;7:(1)56-63.
  44. Master Z, Campo-Engelstein L, Caulfield T. Scientists' perspectives on consent in the context of biobanking research. European Journal of Human Genetics.2015;23:(5)569-574.
  45. Master Z, Robertson K, Frederick D, Rachul C, Caulfield T. Stem cell tourism and public education: the missing elements. Cell Stem Cell.2014;15:(3)167-270.
  46. Zarzeczny A, Caulfield T, Ogbogu U, Bell P, Clark M, Crooks V, Hyde-Lay R, Kamenova K, Master Z, Rachul C, Snyder J, Toews M, Zoeller S. Professional Regulation: A potentially valuable tool in responding to "stem cell tourism". Stem Cell Reports.2014;3:(3)379-384.
  47. Smith E, Hunt M, Master Z. Authorship ethics in global health research partnership between researchers from low and middle income countries and high income countries. BMC Medical Ethics.2014;15:42.
  48. Caufiled T, Burningham S, Joly Y, Master Z, Shabani M, Borry P, Becker A, Burgess M, Calder K, Critchley C, Edwards K, Fullerton SM, Gottweis H, Hyde-Lay R, Illes J, Isasi R, Kato K, Kaye J, Knoppers B, Lynch J, McGuire A, Meslin E, Nicol D, O'Doherty K, Ogbogu U, Otlowski M, Pare P, Pullman D, Ries N, Scott C, Sears M, Wallace H, Zawati MH. A review of the key issues associated with the commercialization of biobanks. Journal of Law and the Biosciences.2014;1:(1)94-110.
  49. Master Z, Resnik DB. Hype and public trust in science. Science and Engineering Ethics.2013;19(2)321-335.
  50. Master Z, Zarzeczny A, Rachul C, Caulfield T. What's Missing? Discussing stem cell translational research in educational information on stem cell "tourism". Journal of Law, Medicine & Ethics.2013;41(1)254-268.
  51. Master Z, Resnik DB. Incorporating exclusion clauses into informed consent for biobanking. Cambridge Quarterly of Healthcare Ethics.2013;22:(2)203-212.
  52. Resnik DB, Master Z. Policies and initiatives aimed at addressing research misconduct in high income countries. PLoS Medicine.2013;10:(3)e1001406.
  53. Master Z, Claudio JO, Rachul C, Wang J, Minden M, Caulfield T. Cancer patient perceptions on the ethical and legal issues related to biobanking. BMC Medical Genomics.2013;6:8.
  54. Master Z, Sipp D. A role patient advocacy in countering the premature commercialization of stem cell interventions. The Monitor.2013;27(5)26-30.
  55. Master Z, Nelson E, Murdoch B, Caulfield T. Biobanks, consent, and claims of consensus. Nature Methods..2012;9:(9)885-888.
  56. Master Z. The ethics and governance of research integrity in Canada. Health Law Review.2012;20(3)5-14.
  57. Master Z, McDonald M, Williams-Jones B. Promoting research on research integrity in Canada. Accountability in Research: Policies and Quality Assurance. 2012; 19(1):47-52.
  58. Master Z, Ogbogu U. Stem cell tourism in the era of personalized medicine: what we know, and what we don't know. Current Pharmacogenomics and Personalized Medicine.2012;10(2)106-110.
  59. Resnik DB, Master Z. Criteria for authorship in bioethics. Am J Bioeth. 2011 Oct; 11 (10):17-21
    View PubMed
  60. Master Z, Resnik DB. Stem-cell tourism and scientific responsibility. Stem-cell researchers are in a unique position to curb the problem of stem-cell tourism. EMBO Rep. 2011 Sep 30; 12 (10):992-5 Epub 2011 Sept 30
    View PubMed
  61. Master Z, Ries N, Caulfield T. Balancing efficiency and the protection of research participants: Canadian allergy/asthma researchers' perspectives on the ethics review of multi-site health research. Journal of Clinical Research and Bioethics.2011;
  62. Master Z, Crozier GK. The ethics of moral compromise for stem cell research policy. Health Care Analysis. 2011; 20(1):50-65.
  63. Master Z. Responsible conduct of bioethics research. Accountability in Research: Policies and Quality Assurance.2011;18:(2)102-119.
  64. Resnik DB, Master Z. Authorship policies in bioethics journals. Journal of Medical Ethics.2011;37:(7)424-428.
  65. Master Z, Resnik DB. Stem-cell researchers are in a unique position to curb the problem of stem-cell tourism. EMBO Reports.2011;12:(10):992-995.
  66. Master Z, Laforce D, McLeod M, Williams-Jones B. The ethics of human embryos and embryonic stem cells. Journal of Stem Cells.2008;3(2)127-161.
  67. Master Z, McLeod M, Medez I. Benefits, risks and ethical considerations in translation of stem cell research into clinical applications in Parkinson's disease. Journal of Medical Ethics.2007;33:(3)169-173.
  68. Master Z, Laforce D, McLeod M, Williams-Jones B. Moral and scientific considerations in embryonic stem cell research. Stem Cell Research Journal.2007;1(3-4)189-239.
  69. Master Z. ES cell gametes: the new frontier in human reproduction. Human Reproduction.2006;21(4)857-863.
  70. Master Z. Embryonic stem cells steam up the ethics of assisted human reproduction. Embryo Talk.2006;1(3)168-175.
  71. Van Slyke P, Coll ML, Master Z, Kim H, Filmus J, Dumont DJ. Dok-R mediates attenuation of epidermal growth factor-dependent mitogen-activated protein kinase and Akt activation through processive recruitment of c-Src and Csk. Molecular and Cellular Biology.2005;25(9)3831-3841.
  72. Voskas D, Jones N, Van Slyke P, Sturk C, Chang W, Haninec A, Babichev YO, Tran J, Master Z, Chen S, Ward N, Cruz M, Jones J, Kerbel RS, Jothy S, Dagnino L, Arbiser J, Klement G, Dumont DJ. A Cyclosporine-Sensitive Psoriasis-Like Disease Produced in Tie2 Transgenic Mice. American Journal of Pathology.2005;166(3)843-855.
  73. Jones N, Chen S, Sturk C, Master Z, Tran J, Kerbel RS, Dumont DJ. A Unique Autophosphorylation Site on Tie2/Tek Mediates Dok-R Phosphotyrosine Binding Domain Binding and Function. Molecular and Cellular Biology.2003;23(8)2658-2668.
  74. Master Z, Truong A. Stem Cells - Hope or Hype for Reproductive Medicine and Regenerative Medicine? Hypothesis.2003;1(1)24-26.
  75. Master Z, Tran J, Bishnoi A, Chen SH, Ebos J, Van Slyke P, Kerbel RS, Dumont DJ. Dok-R binds c-AbI and regulates AbI kinase activity and mediates cytoskeletal reorganization. Journal of Biological Chemistry.2003;278(32)30170-30179.
  76. Ebos JM, Tran J, Master Z, Dumont DJ, Melo JV, Buchdunger E, Kerbel RS. Imatinib Mesylate (STI-571) reduces Bcr-AbI-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. Molecular Cancer Research.2002;1(2)89-95.
  77. Tran J, Master Z, Rak J, Klement G, Dumon DJ, Kerbel RS. VEGF Induces Resistance of Endothelial Cells to Chemotherapy. Proceedings of the National Academy of Sciences.2002;99(7)4349-4354.
  78. Master Z, Jones N, Tran J, Jones J, Kerbel RS, Dumont DJ. Dok-R plays a pivotal role in Angiopoietin-1 mediated cell migration through activation of Pak. EMBO Journal.2001;20:(21)5919-5928.
  79. Teichert-Kuliszewska K, Maisonpierre PC, Jones N, Campbell AI, Master Z, Bendeck MP, Alitalo K, Dumont DJ, Yancopoulos GD, Stewart DJ. Biological actions of angiopoietin-2 in a fibrin matrix model of angiogenesis is associated with activation of Tie2. Cardiovascular Research.2001;49:(3)659-670.
  80. Jones N, Voskas D, Master Z, Sarao R, Jones J, Dumont DJ. Rescue of the early vascular defects in the Tek/Tie-2-null mice reveal an essential survival function. EMBO Reports.2001;2:(5)438-445.
  81. Jones N, Master Z, Jones J, Bouchard D, Gunji Y, Sasaki H, Daly R, Alitalo K, Dumont DJ. Identification of Tek/Tie2 binding partners. Binding to a multifunctional docking site mediates cell survival and migration. Journal of Biological Chemistry.1999;274:(43)30896-30905.